Risperidone-controlled,Multicentre Clinical Trial of Iloperidone in Patients With Schizophrenia

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.288 enrolled

Overview

This research is a Randomized, double-blind, risperidone-controlled, multicenter clinical study. Chinese subjects with Ischemic Schizophrenia.

Subjects will randomly enter into one of two groups,the period of treatment is 8 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

288

Conditions

Schizophrenia

Interventions

IloperidoneDRUG

RisperidoneDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * men and women aged 18 to 65 years with schizophrenia; * PANSS total score of at least 70 at screening and baseline; * at least 2 more than 4 points in 7 of PANSS-P; * informed consent. Exclusion Criteria: * allergy with iloperidone or risperidone; * psychotic symptoms failing to improve after sufficient exposure to 2 antipsychotic treatment; * any other primary Axis 1 psychiatric diagnosis; * a history of alcohol or drug dependence in recent 1 year; * at imminent risk of harm to self or others; * systolic blood pressure≤90mmHg。

Locations (1)

Shanghai Mental Health Center

Shanghai, Shanghai Municipality, China

RECRUITING

Outcomes

Primary Outcomes

the score of Positive and Negative syndrome scale to evaluation the severity of schizophrenia

Time frame: 8 weeks

Secondary Outcomes

the score of clinical global impressions to evaluation the severity of illness

Time frame: 8 weeks

the score of clinical global impressions to evaluation the improvement of illness

Time frame: 8 weeks

Central Contacts

Wang yu mei, master

CONTACT

86-311-67808816

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.